Home › Multiple Myeloma › California › San Francisco
Multiple Myeloma clinical trials in San Francisco, CA
15 studies for Multiple Myeloma are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RecruitingPhase 1
- University of California San Francisco, San Francisco
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- University of California San Francisco, San Francisco
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
RecruitingPhase 2
- University of California San Francisco, San Francisco
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RecruitingPhase 2
- University of California San Francisco, San Francisco
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingPhase 4
- University of California San Francisco, San Francisco
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1/2
- UCSF, San Francisco
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- Kaiser Permanente - South San Francisco Medical Center, San Francisco
- California Pacific Medical Center Research Institute, San Francisco
- Kaiser Permanente - San Francisco Medical Center, San Francisco
- and 1 more
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
RecruitingPhase 1
- University of California, San Francisco, San Francisco
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
- UCSF, San Francisco
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RecruitingPhase 1/2
- Research Site, San Francisco
Delayed Toxicities Post-CAR-T
RecruitingObservational study
- UCSF Medical Center, San Francisco
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
RecruitingPhase 1
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
- University of Calfornia, San Francisco, San Francisco
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO26 studies
- Columbus, OH24 studies
- Rochester, MN24 studies
- Baldwin Park, CA23 studies
- St. Louis, MO23 studies
- Washington, DC22 studies
Other studies in San Francisco
- Prostate Cancer45 studies
- Breast Cancer43 studies
- Non-Small Cell Lung Cancer37 studies
- Cancer (all types)35 studies
- Heart Failure29 studies
- Metastatic Cancer29 studies
- Lung Cancer23 studies
- Melanoma22 studies
- Pancreatic Cancer20 studies
- Colorectal Cancer19 studies
- Cardiovascular Disease18 studies
- Glioblastoma18 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.